Abstracts tagged "dermatomyositis"

Abstract Number: 1347 • 2018 ACR/ARHP Annual Meeting
A Semi-Quantitative Whole Body Magnetic Resonance Imaging Assessment Tool to Define Musculoskeletal Abnormalities in Patients with Idiopathic Inflammatory Myopathies
Sara Faghihi-Kashani¹, Lisa G. Rider², David Bluemke³, Ashkan Malayeri⁴, Evrim Turkbey⁴, Joseph Shrader⁵, John McGrath⁶, Elizabeth Jones⁷, Jamie Marco⁸, Frederick W. Miller⁹ and Adam Schiffenbauer¹⁰, ¹Environmental Autoimmunity Group, National Institute of Environmental Health, Bethesda, MD, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ³Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, ⁵Rehabilitation Medicine, National Institutes of Health, Bethesda, MD, ⁶Social and Scientific Systems, Inc., Durham, NC, ⁷Radiology and Imaging Sciences, National Institutes of Health Clinical Center, Bethesda, MD, ⁸Radiology and Imaging Sciences National Institutes of Health, Bethesda, MD, ⁹Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ¹⁰NIEHS, NIH, Bethesda, MD
Background/Purpose: There is a lack of standardized methodology for assessing whole body MRI (WBMRI) in idiopathic inflammatory myopathy (IIM) patients. This leads to difficulty in…
Abstract Number: 1382 • 2018 ACR/ARHP Annual Meeting
Evaluating Results of an Interferon-γ Release Assay in Patients with Autoimmune Skin Disease on Hydroxychloroquine
Rebecca Gaffney¹ and Victoria P. Werth², ¹Dermatology, University of Pennsylvania, Philadelphia, PA, ²Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: QuantiFERON-TB Gold is commercial interferon-γ release assay used to screen patients for tuberculosis before starting or while on immunosuppressive therapies. Clinical studies on efficacy…
Abstract Number: 1851 • 2018 ACR/ARHP Annual Meeting
Physical Function Trajectories in Children with Juvenile Myositis
Kaveh Ardalan¹, Elizabeth L. Gray², Julia (Jungwha) Lee², Madison L. Wolfe³, Gabrielle A. Morgan⁴ and Lauren M. Pachman⁵, ¹Departments of Pediatrics and Medical Social Sciences, Division of Rheumatology, Northwestern University Feinberg School of Medicine/Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Creighton University School of Medicine, Omaha, NE, ⁴Cure JM Program of Excellence in Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁵Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL
Background/Purpose: Juvenile myositis (JM) is an inflammatory disease that causes muscle weakness, skin rashes, and significant deconditioning. Little is known about long-term resolution of physical…
Abstract Number: 2163 • 2018 ACR/ARHP Annual Meeting
Prevalence and Incidence of Idiopathic Inflammatory Myopathies in Korea:a Nationwide Population-Based Study over 10 Years
Yoon-Kyoung Sung¹, Hyoungyoung Kim², Jisun Myung³, Eunwoo Nam³, Sun-Young Jung⁴, Eun Jin Jang⁵, Dae-Hyun Yoo⁶ and Soo-Kyung Cho², ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ³Biostatistical Consulting and Research Lab, Medical Research Collaborating Center, Hanyang University, Seoul, Korea, Republic of (South), ⁴College of Pharmacy, Chung-Ang University, Seoul, Korea, Republic of (South), ⁵Information Statistics, Andong National University, Andong-si, Korea, Republic of (South), ⁶Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South)
Prevalence and Incidence of idiopathic Inflammatory Myopathies in Korea: a Nationwide Population-based Study over 10 yearsYoon-Kyoung Sung1, Hyoungyoung Kim1, Jisun Myung2, Eunwoo Nam2, Sun-young Jung3,…
Abstract Number: 2169 • 2017 ACR/ARHP Annual Meeting
A Two-Center Experience with Rituximab in Patients with Primary Idiopathic Myositis and Overlap Myositis: A Retrospective Observational Study
Kimberly A. Rehberg¹, Morgan M. Brown², Anna K. Shmagel¹, Elie Gertner³ and Jerry A. Molitor¹, ¹Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, ²HealthPartners Institute, St. Paul, MN, ³Section of Rheumatology, Regions Hospital, St. Paul, MN
Background/Purpose: Recent studies have suggested the possible benefit of the anti-CD20 agent Rituximab (RTX) in autoimmune myositis (AIM). As AIM is a rare and heterogeneous…
Abstract Number: 2170 • 2017 ACR/ARHP Annual Meeting
Near Patient Detection of Anti-MDA5 Antibodies Using Photonic Ring Immunoassays
Makoto Miyara¹, Rémi Chieze², Yurdagul Uzunhan³, Jean- Luc Charuel⁴, Pascale Ghillani-Dalbin⁴, Sasi Mudumba⁵, Alice Wu⁵, Hilario Nunes³, Zahir Amoura⁶, Rufus Burlingame⁵ and Lucile Musset¹, ¹Department of immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ²department of Immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ³Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ⁴Department of Immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ⁵Genalyte Inc., San Diego, CA, ⁶Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France
Background/Purpose: The presence of anti-MDA5 antibody is associated with amyopathic dermatomyositis and/or rapidly progressive interstitial lung disease that can be fatal.In the latter case, it…
Abstract Number: 851 • 2017 ACR/ARHP Annual Meeting
Autoantibodies Predict Long Term Survival in Myositis Associated Interstitial Lung Disease
Silvia Martinez¹, Rohit Aggarwal^2,3 and Chester V. Oddis⁴, ¹Internal Medicine, UPMC, pittsburgh, PA, ²Department of Medicine / Rheumtology, University of Pittsburgh Medical Center, Pittsburgh, PA, ³Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Rheumatology/Clinical Immunology, Unviersity of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Interstitial lung disease (ILD) significantly contributes to morbidity and mortality in adult polymyositis (PM) and dermatomyositis (DM). Myositis associated autoantibodies (MAA) are associated with…
Abstract Number: 2172 • 2017 ACR/ARHP Annual Meeting
Clinical Significance of Serum Levels of Anti-Transcriptional Intermediary Factor 1-γ Antibody in Patients with Dermatomyositis
Nobuaki Ikeda, Yukie Yamaguchi, Miwa Kanaoka, Yasushi Ototake, Eriko Takebayashi and Michiko Aihara, Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Background/Purpose: Dermatomyositis (DM) is an autoimmune inflammatory disease characterized by skin eruptions and myositis, which is occasionally complicated by interstitial lung disease (ILD) or concomitant…
Abstract Number: 854 • 2017 ACR/ARHP Annual Meeting
Predictive Modeling of Mortality in Polymyositis/Dermatomyositis Patients with Interstitial Lung Disease Based on Combination of Serum Myositis-Specific Autoantibodies and Conventional Biomarkers
Takahisa Gono¹, Kenichi Masui², Yasushi Kawaguchi³, Kei Ikeda⁴, Atsushi Kawakami⁵, Maasa Tamura⁶, Yoshinori Tanino⁷, Takahiro Nunokawa⁸, Yuko Kaneko⁹, Shinji Sato¹⁰, Katsuaki Asakawa¹¹, Naoshi Nishina⁹ and Masataka Kuwana¹, ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²Department of Anesthesiology, National Defense Medical College School of Medicine, Tokorozawa, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, ⁵Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Japan, ⁶Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁷Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan, ⁸Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ⁹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹⁰Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, ¹¹Division of Respiratory Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan
Background/Purpose: Interstitial lung disease (ILD) is one of the leading causes of mortality in patients with polymyositis or dermatomyositis (PM/DM). Since clinical courses and outcomes…
Abstract Number: 2173 • 2017 ACR/ARHP Annual Meeting
Characteristics Unique to MDA5 and Anti-Ro/SSA-52 Kda Dual Antibody Positive Patients with Inflammatory Myopathies
Juan J Maya, Olga Pinkston, Florentina Berianu, Benjamin Wang and Andy Abril, Rheumatology, Mayo Clinic Florida, Jacksonville, FL
Background/Purpose: The anti-melanoma differentiation-associated gene 5 antibody (MDA5) was recently classified as a myositis-specific antibody (MSA), and has been associated with rapidly progressive interstitial lung…
Abstract Number: 1732 • 2017 ACR/ARHP Annual Meeting
The Characteristic T-Cell Receptor-Mediated Signaling of Peripheral Blood T Cells in Dermatomyositis and Polymyositis
Yasuhiro Shimojima¹, Dai Kishida² and Yoshiki Sekijima², ¹Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan, ²Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan
Background/Purpose: In dermatomyositis (DM) and polymyositis (PM), the characteristics of T cell expression in peripheral blood have been previously described; especially, decreased expression of interferon-γ…
Abstract Number: 2613 • 2017 ACR/ARHP Annual Meeting
Antimalarial Drug Toxicities in Rheumatic Skin Disease Patients
Lavanya Mittal¹, Lingqiao Zhang², Rui Feng² and Victoria Werth¹, ¹Department of Dermatology, Corporal Michael J. Crescenz VAMC, Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Department of Biostatistics and Epidemiology at the Hospital of the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Although existing evidence demonstrates the efficacy of antimalarials for rheumatic skin disease, the safety of these medications, and particularly quinacrine, remain debated. Quinacrine may…
Abstract Number: 1801 • 2017 ACR/ARHP Annual Meeting
Quantifying Clinical and Economic Outcomes Associated with Chronic Corticosteroid Exposure in a US Population
J. Bradford Rice¹, Alan White¹, Andrea Lopez¹, Aneesha Wagh¹, Yimin Qin², Ghaith Mitri², Laura Bartels-Peculis², Gosia Ciepielewska² and Winnie Nelson³, ¹Analysis Group, Inc., Boston, MA, ²Mallinckrodt Pharmaceuticals, Hampton, NJ, ³Health Economics and Outcomes Research, Mallinckrodt Pharmaceuticals, Hampton, NJ
Background/Purpose: Corticosteroids (CS) are commonly used for rheumatologic conditions, and known to cause systemic adverse events (AEs), particularly when used at high doses for prolonged…
Abstract Number: 2130 • 2017 ACR/ARHP Annual Meeting
Joint Manifestations in Patients Diagnosed with Idiopathic Inflammatory Myopathy: Multicenter Registry on Inflammatory Myositis from the Rheumatology Society in Madrid, Spain
Larissa Valor¹, Diana Hernández-Flórez², Julia Martínez-Barrio³, Beatriz E. Joven⁴, Laura Nuño⁵, Carmen Larena⁶, Irene Llorente⁷, Carmen Barbadillo⁸, Paloma Garcia De La Peña⁹, Lucía Ruíz Gutiérrez¹⁰, Henry Moruno Cruz¹¹, Tatiana Cobo-Ibáñez¹², Raquel Almodóvar González¹³, Leticia Lojo¹⁴, MARIA JESUS GARCIA DE YEBENES Y PROUS¹⁵ and Francisco Javier López Longo¹⁶, ¹Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Rheumatology, Gregorio Marañón University General Hospital, Madrid, Spain, ³Servicio de Reumatologia, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁴Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁵Servicio de Reumatologia, Hospital Universitario La Paz, Madrid, Spain, ⁶Hospital Gregorio Marañón, Madrid, Spain, ⁷Rheumatology, H.U. La Princesa, Madrid, Spain, ⁸Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁹Rheumatology, Hospital Madrid Norte Sanchinarro, Madrid, Spain, ¹⁰Pediatric Rheumathology Unit, University Children's Hospital Niño Jesús, Madrid, Spain, ¹¹University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcalá de Henares, Madrid, Spain, ¹²Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ¹³Rheumatology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain, ¹⁴Rheumatology, Hospital Universitario La Paz, Spain, Spain, ¹⁵Institute for Musculoskeletal Health, Madrid, Spain, ¹⁶Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
Background/Purpose: Idiopathic inflammatory myopathies (IIM) comprise a heterogeneous group of autoimmune conditions characterized by muscle non-suppurative inflammation, progressive muscle weakness and a variety of extra-muscular…
Abstract Number: 2132 • 2017 ACR/ARHP Annual Meeting
Angiogenesis and VEGF-Expressing Cells Are Identified Predominantly in the Fascia Rather Than the Muscle in the Early Phase of Dermatomyositis
Ken Yoshida^1,2, Haruyasu Ito¹, Kazuhiro Furuya¹, Taro Ukichi¹, Kentaro Noda¹ and Daitaro Kurosaka¹, ¹Division of Rheumatology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan, ²Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
Background/Purpose: We previously showed that fasciitis is a frequent manifestation of the disease in dermatomyositis (DM) but not in polymyositis (PM) and that DM-associated fasciitis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].